Evidence map›Paper›PMID 21537039›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Carol Aghajanian, Michael W Sill, Kathleen M Darcy, Benjamin Greer, D Scott McMeekin, Peter G Rose, Jacob Rotmensch, Mack N Barnes, Parviz Hanjani, Kimberly K Leslie

4 registry-linked trialsAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 125 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02584478 phase3unknown statusnot on this mapstarted 2015, after this paper: background citation

A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma

TypeinterventionalSponsorAdvenchen Laboratories, LLCRan2015 to 2024Enrolled294ConditionsEndometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal CarcinomaArmsAL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin
NCT03694262 phase2completednot on this mapstarted 2019, after this paper: background citation

An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

TypeinterventionalSponsorMedical College of WisconsinRan2019 to 2026Enrolled30ConditionsEndometrial Cancer, Uterine CarcinosarcomaArmsRucaparib, Bevacizumab, Atezolizumab
NCT04197219 phase2withdrawnnot on this mapstarted 2021, after this paper: background citation

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer With Deficient Mismatch Repair System Post PD1 Exposure: Phase II Trial

TypeinterventionalSponsorCase Comprehensive Cancer CenterRan2021 to 2026Enrolled0ConditionsRecurrent Endometrial CancerArmsPembrolizumab, Axitinib
NCT04486352 phase1 / phase2recruitingnot on this mapstarted 2021, after this paper: background citation

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

TypeinterventionalSponsorAlliance Foundation Trials, LLC.Ran2021 to 2027Enrolled148ConditionsEndometrial CancerArmsAtezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  3. A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  4. Trial
  5. Trial
  6. A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  7. Trial
  8. Trial
  9. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  10. Trial
  11. Trial
  12. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carol AghajanianGynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. aghajanc@mskcc.org
Michael W Sill
Kathleen M Darcy
Benjamin Greer
D Scott McMeekin
Peter G Rose
Jacob Rotmensch
Mack N Barnes
Parviz Hanjani
Kimberly K Leslie

Funding

GYNECOLOGIC ONCOLOGY GROUP HEADQUARTERSU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI DISAIA, PHILIP J. · 1985 to 2013
$132.6M
GYNECOLOGIC ONCOLOGY GROUP STATISTICAL OFFICEU10CA037517 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI BLESSING, JOHN A · 1985 to 2013
$67.4M
Gynecologic Oncology Group Specimen BankingU24CA114793 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI DISAIA, PHILIP J. · 2005 to 2014
$7.0M
Targeted Therapy for Endometrial CancerR01CA099908 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LESLIE, KIMBERLY K. · 2002 to 2023
$5.8M
NCI NIH HHS R01 CA099908NCI NIH HHS R01CA99908NCI NIH HHS U10 CA027469NCI NIH HHS U10 CA037517NCI NIH HHS U10CA27469NCI NIH HHS U10CA37517NCI NIH HHS U24 CA114793NCI NIH HHS U24CA114793
6 · The paper itself

Abstract

purposeBevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types. We conducted a phase II trial to assess the activity and tolerability of single-agent bevacizumab in recurrent or persistent endometrial cancer (EMC). PATIENTS AND

methodsEligible patients had persistent or recurrent EMC after receiving one to two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of ≤ 2. Treatment consisted of bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression or prohibitive toxicity. VEGF-A was assessed by immunohistochemistry in archival tumor and by enzyme-linked immunosorbent assay in pretreatment plasma. Primary end points were progression-free survival (PFS) at 6 months and overall response rate.

resultsFifty-six patients were enrolled. Fifty-two patients were eligible and evaluable. Median age was 62 years, and prior treatment consisted of one or two regimens in 33 (63.5%) and 19 (36.5%) patients, respectively. Twenty-nine patients (55.8%) received prior radiation. Adverse events were consistent with those expected with bevacizumab treatment. No GI perforations or fistulae were seen. Seven patients (13.5%) experienced clinical responses (one complete response and six partial responses; median response duration, 6.0 months), and 21 patients (40.4%) survived progression free for at least 6 months. Median PFS and overall survival times were 4.2 and 10.5 months, respectively. Suggested associations were observed between high VEGF-A and adjusted hazard of death or tumor response when evaluated in tumor/plasma or plasma, respectively.

conclusionBevacizumab is well tolerated and active based on PFS at 6 months in recurrent or persistent EMC and warrants further investigation.

Indexed as

AdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansKaplan-Meier EstimateMiddle AgedNeoplasm Recurrence, LocalSalvage TherapyVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabVascular Endothelial Growth Factor A

Identifiers

PMID21537039
PMCPMC3107744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.